SPC
ATNM icon

Sigma Planning Corp’s Actinium Pharmaceuticals ATNM Stock Holding History

Sigma Planning Corp’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-333
Closed -$14K – 737
2016
Q3 		$14K Buy
+333
New +$17.1K ﹤0.01% 741

Other funds holding ATNM

SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sigma Planning Corp's ATNM Position: Q4 2016 in Review

Sigma Planning Corp sold out of Actinium Pharmaceuticals (ATNM) in Q4 2016, closing a stake of 333 shares — an estimated $14K sold.

Sigma Planning Corp first reported a position in ATNM in Q3 2016 and held it in 1 quarter. The position peaked at $14K in Q3 2016. 30 funds tracked by Wall St. Rank hold ATNM as of Q4 2016.

  • Sigma Planning Corp reported no remaining Actinium Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Sigma Planning Corp sold 333 Actinium Pharmaceuticals shares in Q4 2016, an estimated $14K.
  • Sigma Planning Corp first reported a position in Actinium Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Sigma Planning Corp's Actinium Pharmaceuticals position peaked at $14K in Q3 2016.
  • 30 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2016.

Based on Sigma Planning Corp's 13F filing for Q4 2016, filed 23 Jan 2017.